SCHEMBL21726306

SCHEMBL21726306

COc1cc(OC)cc(-c2ccc3cnn(PI)c3c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.44
ABCB1 P08183 4/20 0.44
BCR P11274 4/20 0.44
HSD17B1 P14061 1/20 0.44
HSD17B2 P37059 1/20 0.44
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP1A1 P04798 2/20 0.40
CYP1B1 Q16678 2/20 0.40
CYP2E1 P05181 1/20 0.40
CYP2C8 P10632 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2A6 P11509 1/20 0.40
CYP4B1 P13584 1/20 0.40
CYP2B6 P20813 1/20 0.40
CYP3A5 P20815 1/20 0.40
CYP2A7 P20853 1/20 0.40
CYP3A7 P24462 1/20 0.40
CYP2F1 P24903 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21726329 0.80 LRRK2 (0.34) CYP1A2CYP3A4CYP2C9CYP1A1CYP1B1
SCHEMBL21726304 0.77 RAB9A (0.43) ABL1ABCB1BCRHSD17B1HSD17B2
SCHEMBL21726330 0.76 MAP4K1 (0.34) BRD4CYP11B1CYP11B2
SCHEMBL21726299 0.76 FGFR4 (0.46) CYP11B1CYP11B2FGFR3HTR2AHTR2C
SCHEMBL30206772 0.74 ABL1 (0.47) ABL1ABCB1BCRHSD17B1HSD17B2
SCHEMBL21726310 0.71 CYP1A1 (0.42) CYP1A2CYP3A4CYP2C9CYP1A1CYP1B1
SCHEMBL22753215 0.69 HTR2A (0.49) HSD17B1CYP1A2CYP3A4CYP11B1CYP11B2
SCHEMBL17530953 0.67 RXRA (0.51) ABL1ABCB1BCRHSD17B1HSD17B2
SCHEMBL20437532 0.66 HTR2A (0.34) HTR2AHTR2CHTR2B
SCHEMBL30620457 0.64 ABL1 (0.47) ABL1ABCB1BCRHSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10562900-B2 Indazole compounds as FGFR kinase inhibitor, preparation and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) 2020-02-18 US disclosed
US-20170275291-A1 INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) 2017-09-28 US disclosed
EP-3184521-A1 INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF Shanghai Haihe Pharmaceutical Co., Ltd. (CN) 2017-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562900-B2 Indazole compounds as FGFR kinase inhibitor, preparation and use thereof FGFR1, FGFR2, FGFR3 ABL1 11/4885ABCB1 218/4885BCR 121/4885
US-20170275291-A1 INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF FGFR1, FGFR2, FGFR3 ABL1 11/4885ABCB1 218/4885BCR 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.